- Centers & Specialties
- Clinical Interests
- Proton Radiation Therapy
- Ewing's sarcoma
- Brachytherapy (radioactive seeds)
- IORT (Intraoperative Radiation Therapy)
- Medical Education
- MD, Harvard Medical School
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Therapeutic Radiology
- Foreign Languages
- Boston: Massachusetts General Hospital
- Patient Gateway
- Yes, learn more
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - New York
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Adult and Pediatric
Thomas F. DeLaney, M.D. is a graduate of Harvard College and Harvard Medical School. He trained in Radiation Oncology at the Massachusetts General Hospital (MGH) and spent 6 years as Senior Investigator at the National Cancer Institute. Since 1992, he has been on staff at MGH where he is the Medical Director of the Francis H. Burr Proton Therapy Center and Co-Director of the Center for Sarcoma and Connective Tissue Oncology. He is Professor of Radiation Oncology at Harvard Medical School.
Dr. DeLaney has made important contributions to the treatment of soft tissue sarcomas, bone sarcomas and chordomas, as well as the use of charged particle (proton) radiation therapy. His bibliography lists him as lead author or co-author of 92 original articles in peer-reviewed research publications, as well as 77 reviews, chapters and editorials. He is on the editorial boards of Journal of Surgical Oncology, Journal of Clinical Oncology and UpToDate in Oncology.
- Research Summary
My major research efforts have been in the development and testing of innovative cancer treatment approaches in clinical trials. Primary areas of interest have been soft tissue and bone sarcomas in adults and adolescents, as well as the application of advanced radiation oncology technologies including charged particle radiation with protons and brachytherapy (i.e. placement of radiation sources in close proximity to the tumor to deliver high doses of radiation to the tumor while sparing nearby normal tissue).
- DeLaney TF et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Rad Oncol Biol Phys. 2003;56:1117-27.
- DeLaney TF et al. Phase II study of high dose photon/proton radiotherapy in the management of spine sarcomas. Int J Rad Oncol Biol Phys 2009; 74: 732-9.
- Kepka L, DeLaney TF, et al. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Rad Oncol Biol Phys 2005; 63:852-9.
The MGH Cancer Center has added pencil-beam scanning to the radiation therapy modalities offered at the hospital’s Burr Proton Therapy Center.
55 Fruit Street
Boston, MA 02114-2696